SMD-3236 / SK Bio - LARVOL DELTA

SK Life Science Labs, a Subsidiary of SK Biopharmaceuticals, Presents Discovery of Oral SMARCA2 Degraders Data at 6th Annual Targeted Protein Degradation Summit (PRNewswire-Asia) - "SK Life Science Labs...will present preclinical data supporting its SMARCA protein degradation discovery program at the 6th Annual Targeted Protein Degradation (TPD) Summit. The presentation will highlight the discovery and characterization of SMARCA2 heterobifunctional degraders demonstrating selective SMARCA2 degradation leads to targeted growth inhibition of SMARCA4 mutant cancer cell lines, and share results of in vivo efficacy in a solid tumor xenograft model....Preclinical data show SK Life Science Labs compounds have robust anti-tumor efficacy in vivo and oral leads have demonstrated potent selective degradation of SMARCA2 with selective inhibition of proliferation of SMARCA4 mutant cells."

New molecule • Preclinical • Solid Tumor